Loading…
← CockpitCompetitor Analysis › COLL Collegium Pharmaceutical, Inc.Open in the cockpit ↗

Collegium Pharmaceutical, Inc.COLLCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum neutral 44
Mkt cap
$806M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$15.0M
20-day average traded
Fwd P/E
3.7×
forward earnings
ROIC−WACC
+0.6 pp
WACC 6.9%
Hurdle
-23 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$25.93
1D+1.5%
1W+4.5%
1M+11.6%
3M-5.8%
6M-24.2%
YTD-44.0%
1Y-42.8%
ATR %3.5%
Beta0.16
52w lowhigh48.9% off high

What Collegium Pharmaceutical does

Employees: 423

Collegium Pharmaceutical at a glance

Size Collegium Pharmaceutical (COLL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $806M, the 2363rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.93 on 18 Nov 2026.

Performance Over six months the shares fell 24.2%, against -7.5% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue grew 7.7% over the last twelve months (peer median +2.1%); the operating margin is 15.4% (peer median 5.0%).

Valuation It trades at 3.7× forward earnings against a peer median of 19.6× (2nd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points above its cost of capital (6.9% WACC).

Credit Collegium Pharmaceutical has 1 bond outstanding ($242M).

Short interest Short interest is 16.7% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 93COLL 75
Six months, rebased to 100: Collegium Pharmaceutical against the median of its 20 peers (local-currency closes).

Collegium Pharmaceutical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$815M$781M$631M$567M$464M
Revenue growth—+24%+11%+22%—
Gross profit$481M$463M$377M$326M$212M
EBITDA$359M$413M$360M$325M$204M
Net income$38.2M$62.9M$69.2M$48.2M-$25.0M
Free cash flow$336M$328M$203M$274M$123M
Capital expenditure$1.73M$1.74M$1.65M$461,000$1.62M
Total debt$1.21B$936M$980M$674M$709M

Quarterly statements and history in the cockpit →

Collegium Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%SUVEN688073RIGL6078SANOFIORICGUDIRWD002082603229002349ARDX300267000411BLISSGVS002390COLL6-month return →1-month return →
Up and to the right = strong over both horizons. Collegium Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×688073RIGL6078SANOFIGUDIRWDARDXCOLLRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Collegium Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-25%0%25%688073RIGL6078SANOFI002082002349BLISSGVS002390COLLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Collegium Pharmaceutical is the large dot.

Collegium Pharmaceutical competitors and peer comparison

How Collegium Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Collegium Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
MeasureCOLLPeer medianRank in peer set
1-month return+11.6%-3.8%3rd highest of 19
6-month return-24.2%-7.5%6th lowest of 19
Distance from 52-week high-48.9%-32.8%3rd lowest of 19
Revenue growth (TTM)+7.7%+2.1%7th highest of 19
Operating margin15.4%5.0%7th highest of 19
Forward P/E3.7×19.6×2nd cheapest of 8
Growth the price implies (Req g, 7 yrs)-2.6%6.6%2nd least demanding of 10
Growth delivered (Del g)+20.3%+10.1%4th highest of 10
Hurdle (Req g minus delivered)-22.9 pp-5.1 ppleast demanding of 10
ROIC minus cost of capital+0.6 pp-2.3 pp7th highest of 18
EV / EBITDA5.2×10.0×2nd cheapest of 7
Net debt / EBITDA2.9×-0.5×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a

Collegium Pharmaceutical bonds and credit

Collegium Pharmaceutical has 1 bond outstanding with $242M face value.

Every bond, yield and spread in the cockpit →

Questions

Which companies are Collegium Pharmaceutical's closest peers?
The cockpit's peer set: Suven Life Sciences (SUVEN.NS), Bide Pharmatech (688073.SS), Rigel Pharmaceuticals (RIGL), Hygeia Healthcare (6078.HK), Sanofi India (SANOFI.NS), Oric Pharmaceuticals (ORIC), Knight Therapeutics (GUD.TO), Ironwood Pharmaceuticals (IRWD).
Is Collegium Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 3.7× against a peer median of 19.6×, 2nd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has Collegium Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.2% against -7.5% for the median peer; over one year -42.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.